- Home
- BWB vs ATXS Comparison
BWB vs ATXS Comparison
Compare BWB & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWB
- ATXS
- Stock Information
- Founded
- BWB 2005
- ATXS 2008
- Country
- BWB United States
- ATXS United States
- Employees
- BWB N/A
- ATXS N/A
- Industry
- BWB Major Banks
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- BWB Finance
- ATXS Health Care
- Exchange
- BWB Nasdaq
- ATXS Nasdaq
- Market Cap
- BWB 347.0M
- ATXS 401.2M
- IPO Year
- BWB 2018
- ATXS 2015
- Fundamental
- Price
- BWB $15.02
- ATXS $5.86
- Analyst Decision
- BWB Strong Buy
- ATXS Strong Buy
- Analyst Count
- BWB 2
- ATXS 7
- Target Price
- BWB $18.00
- ATXS $32.43
- AVG Volume (30 Days)
- BWB 62.0K
- ATXS 479.1K
- Earning Date
- BWB 07-23-2025
- ATXS 08-11-2025
- Dividend Yield
- BWB N/A
- ATXS N/A
- EPS Growth
- BWB N/A
- ATXS N/A
- EPS
- BWB 1.10
- ATXS N/A
- Revenue
- BWB $111,392,000.00
- ATXS N/A
- Revenue This Year
- BWB $32.02
- ATXS N/A
- Revenue Next Year
- BWB $11.47
- ATXS N/A
- P/E Ratio
- BWB $13.65
- ATXS N/A
- Revenue Growth
- BWB 3.73
- ATXS N/A
- 52 Week Low
- BWB $10.76
- ATXS $3.56
- 52 Week High
- BWB $16.34
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- BWB 51.97
- ATXS 62.16
- Support Level
- BWB $14.80
- ATXS $5.43
- Resistance Level
- BWB $15.35
- ATXS $5.97
- Average True Range (ATR)
- BWB 0.27
- ATXS 0.44
- MACD
- BWB -0.01
- ATXS 0.06
- Stochastic Oscillator
- BWB 67.00
- ATXS 82.37
About BWB Bridgewater Bancshares Inc.
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering them a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.